1. Home
  2. IVVD vs PFX Comparison

IVVD vs PFX Comparison

Compare IVVD & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • PFX
  • Stock Information
  • Founded
  • IVVD 2020
  • PFX 2010
  • Country
  • IVVD United States
  • PFX United States
  • Employees
  • IVVD N/A
  • PFX N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • PFX Finance: Consumer Services
  • Sector
  • IVVD Health Care
  • PFX Finance
  • Exchange
  • IVVD Nasdaq
  • PFX Nasdaq
  • Market Cap
  • IVVD 123.8M
  • PFX 101.2M
  • IPO Year
  • IVVD 2021
  • PFX N/A
  • Fundamental
  • Price
  • IVVD $0.65
  • PFX $49.25
  • Analyst Decision
  • IVVD Strong Buy
  • PFX
  • Analyst Count
  • IVVD 3
  • PFX 0
  • Target Price
  • IVVD $7.52
  • PFX N/A
  • AVG Volume (30 Days)
  • IVVD 1.8M
  • PFX 739.0
  • Earning Date
  • IVVD 05-15-2025
  • PFX 05-06-2025
  • Dividend Yield
  • IVVD N/A
  • PFX 5.56%
  • EPS Growth
  • IVVD N/A
  • PFX N/A
  • EPS
  • IVVD N/A
  • PFX 5.09
  • Revenue
  • IVVD $25,384,000.00
  • PFX $24,036,577.00
  • Revenue This Year
  • IVVD $606.63
  • PFX $16.80
  • Revenue Next Year
  • IVVD $83.30
  • PFX $0.74
  • P/E Ratio
  • IVVD N/A
  • PFX $9.68
  • Revenue Growth
  • IVVD N/A
  • PFX 15.02
  • 52 Week Low
  • IVVD $0.36
  • PFX $43.80
  • 52 Week High
  • IVVD $2.74
  • PFX $57.40
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 52.71
  • PFX 36.35
  • Support Level
  • IVVD $0.52
  • PFX $48.99
  • Resistance Level
  • IVVD $0.80
  • PFX $51.08
  • Average True Range (ATR)
  • IVVD 0.08
  • PFX 0.27
  • MACD
  • IVVD 0.01
  • PFX -0.01
  • Stochastic Oscillator
  • IVVD 50.70
  • PFX 54.59

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: